| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.6 | 1.3 |
| Net income | 1.8 | 0.9 |
| EPS (diluted, $ a share) | $0.29 | $0.62 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +105.0% |
|---|---|
| Revenue, year on year | +24.3% |
| Operating margin | -51.8% |
10-Q filed with the SEC, NASDAQ: RKDA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Arcadia Biosciences, Inc.: key numbers
- Share price
- $0.1936Close, Nov 16
- Market cap
- $1.17M
- Shares outstanding
- 6.07MLatest SEC cover page
- Sector
- Energy & Transportation
- Industry
- Crude Petroleum & Natural GasSIC 1311
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Arcadia Biosciences, Inc.
All →Arcadia Biosciences Financial Results
Arcadia Biosciences reported third-quarter 2026 financial results, highlighted by a 24% year-over-year increase in total revenues to $1.6 million. The growth was primarily driven by record quarterly sales for the Zola coconut water brand, which benefited from strong summer promotional programs and expanded distribution.
- Term
- Q3 2026
“The third quarter was very strong for Zola® with revenues growing 24% compared to the same quarter last year, resulting in the highest quarterly sales the brand has ever reported.”
T.J. Schaefer, CEO of Arcadia
“We are extremely excited to begin shipping our newly formulated espresso flavor this month after receiving pre-launch commitments from several of our leading customers.”
T.J. Schaefer, CEO of Arcadia
Arcadia Biosciences Shareholder Meeting
Arcadia Biosciences held its 2026 Annual Meeting of Stockholders where shareholders elected Gregory D. Waller as a Class II director and approved the new 2026 Omnibus Equity Incentive Plan. Stockholders also approved a potential reverse stock split at a ratio between 1-for-2 and 1-for-10, to be implemented at the Board's discretion before June 30, 2027, and ratified executive compensation.